Enterprise record
Alpha ID: alpha:company:994f0aa1-40ac-431e-a75c-0aa8be4df41aVersion: public-1
20 published Claims4 sources
Governance record
Record overview
Explore Entrada Therapeutics, Inc.'s published governance Claims, committee structure, and linked sources. Each item reflects the scope and dates of its source.
About this record →- Company
- Entrada Therapeutics, Inc.
- Published Claims
- 20
- Evidence records
- 4
- Record version
- public-1
Record highlights
Only published Claims appear in these highlights.
Financials →
No source-linked Claim published yet.
Shareholders →
No source-linked Claim published yet.
Compensation →
No source-linked Claim published yet.
Legal →
No source-linked Claim published yet.
Committee overview
Committee summaries link to the published Claim and its source evidence.
A committee summary is not published in this record. Review the Board section for available leadership and appointment Claims.
Key governance topics
Counts describe published Claims in this record.
Key Claims
Board and committees
Financial statements
Published financial observations retain their reported values, periods, and sources. Coverage may be partial; this is not a reconstructed complete financial statement.
All financials coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageControl and shareholders
Control and shareholders coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageCompensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAuditors, advisors and reporting
Auditors, advisors and reporting coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageLegal
Legal coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAI governance
AI governance coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageEvidence, history and coverage
Additional published Claims
Published evidence records
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Oct 5, 2026
Supports 3 claims
- Legal Name: Entrada Therapeutics, Inc. · Claim reviewed: Oct 5, 2026
- Entity Status: Public listing published · Claim reviewed: Oct 5, 2026
- Published Fact: US · Claim reviewed: Oct 5, 2026
SEC DEF 14A 0001689375-26-000021
sec def 14a · Source published: Apr 24, 2026 · Retrieved: Sep 13, 2026
Supports 8 claims
- Leadership Role: Kush M. Parmar, M.D., Ph.D.: Board Chairman · Claim reviewed: Oct 5, 2026
- Leadership Role: Bernhardt Zeiher, M.D.: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Maha Radhakrishnan, M.D.: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Peter S. Kim, Ph.D.: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Dipal Doshi: Chief Executive Officer · Claim reviewed: Oct 5, 2026
- Leadership Role: Kory Wentworth: Chief Financial Officer · Claim reviewed: Oct 5, 2026
- Leadership Role: Natarajan Sethuraman, Ph.D.: President of Research and Development · Claim reviewed: Oct 5, 2026
- Leadership Role: Nathan J. Dowden: President and Chief Operating Officer · Claim reviewed: Oct 5, 2026
DEF 14A trda-20260424.htm
sec proxy · Source published: Apr 24, 2026 · Retrieved: Sep 2, 2026
Supports 8 claims
- Leadership Role: Bernhardt Zeiher: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Dipal Doshi: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Gina Chapman: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Kush M. Parmar: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Maha Radhakrishnan: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Mary Thistle: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Natarajan Sethuraman: Director · Claim reviewed: Oct 5, 2026
- Leadership Role: Peter S. Kim: Director · Claim reviewed: Oct 5, 2026
TRDA DEF 14A executive officers
sec filing · Source published: Apr 24, 2026 · Retrieved: May 5, 2026
Supports 1 claim
- Leadership Role: Natarajan Sethuraman: President of Research and Development · Claim reviewed: Oct 5, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-05
- Board and committees
- published
- Financial statements
- not observed
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed